Pharma R&D productivity seen improving for the first time in years - Deloitte
Seeking Alpha News (Sat, 4-May 3:30 PM ET)
Sanofi’s Frexalimab Shows Promise in MS Trial
TipRanks (Thu, 2-May 4:59 PM ET)
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Benzinga (Thu, 2-May 3:49 PM ET)
Regeneron falls after Q1 miss; announces $3B share buybacks
Seeking Alpha News (Thu, 2-May 7:55 AM ET)
PRNewswire (Fri, 26-Apr 8:02 AM ET)
Business Wire (Tue, 20-Feb 8:30 AM ET)
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Sanofi - American Depositary Shares trades on the NASDAQ stock market under the symbol SNY.
As of May 7, 2024, SNY stock price climbed to $49.46 with 478,542 million shares trading.
SNY has a beta of 0.94, meaning it tends to be less sensitive to market movements. SNY has a correlation of 0.18 to the broad based SPY ETF.
SNY has a market cap of $123.51 billion. This is considered a Large Cap stock.
Last quarter Sanofi - American Depositary Shares reported $11 billion in Revenue and $.97 earnings per share. This beat revenue expectation by $294 million and exceeded earnings estimates by $.03.
In the last 3 years, SNY stock traded as high as $58.10 and as low as $36.91.
The top ETF exchange traded funds that SNY belongs to (by Net Assets): FVD, GCOW, PID, PPH, PVAL.
SNY has underperformed the market in the last year with a return of -7.9%, while the SPY ETF gained +27.2%. In the last 3 month period, SNY fell short of the market, returning +5.1%, while SPY returned +5.2%. However, in the most recent 2 weeks SNY has outperformed the stock market by returning +4.9%, while SPY returned +3.7%.
SNY support price is $48.63 and resistance is $50.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNY stock will trade within this expected range on the day.